Atherosclerosis Mechanisms

Atherosclerosis is a systemic disease affecting various arterial segments. It arises from complex interactions among lipid metabolism, coagulation system factors, circulating blood cells, cells of the vascular wall (including macrophages and smooth muscle cells), hemodynamic factors, and behavioral risk factors. In the mechanism of initiation and progression of the early stages of atherosclerosis, the composition and level of serum lipoproteins, the state of the endothelium, proliferation of smooth muscle cells (SMCs) in the vascular intima, and the degree of platelet-vascular and plasma hemostasis activation are of critical importance.

The direct link between atherosclerosis and thrombosis positions leech SGS as a potential factor impeding both thrombus formation and, to a certain extent, the development of atherosclerosis itself. SGS addresses the atherosclerotic process through at least three distinct preclinical mechanisms: enzymatic lipid hydrolysis, inhibition of thrombin-mediated vascular smooth muscle cell (SMC) proliferation, and modulation of endothelial function. These findings are preclinical and do not constitute evidence of therapeutic efficacy.

An association between increased blood coagulability and hyperlipidemia has been established (Griffin et al., 2001). Hyperlipidemia contributes to thrombin generation, leading to elevated risk of arterial thrombosis in affected patients. Treatment of hyperlipidemias with statins reduces the risk of arterial thrombotic events (Rosenson & Tangney, 1998). Hypertriglyceridemia is accompanied by increased prothrombin activation and enhanced thrombin generation (Moyer et al., 1998). Simultaneously, a decrease in protein C activation is observed, and protein C deficiency constitutes a recognized risk factor for venous thrombosis (Griffin et al., 2001).

This bidirectional relationship between lipid metabolism and coagulation is central to understanding why SGS — primarily characterized as an anticoagulant secretion — also has anti-atherosclerotic properties. The coagulation-lipid nexus operates through several interconnected pathways:

SGS reduces triglyceride and cholesterol levels by virtue of its triglyceride lipase and cholesterol esterase activities (Baskova et al., 1984). These enzymatic activities were characterized using radiolabeled substrates: glycerol-3-[1-¹⁴C]-oleate for lipase activity and cholesterol-[1-¹⁴C]-oleate for cholesterol esterase activity, with SGS at a protein concentration of 1.7 mg/mL. The lipase activity of SGS is more pronounced than its cholesterol esterase activity, as reflected in the steeper initial reaction rate with glycerol trioleate compared with cholesterol oleate.

Enzymatic Rate Comparison

These enzymatic activities represent a direct mechanism by which SGS can modify the local lipid environment at the leech bite site and, when delivered systemically via the pharmaceutical formulation Piyavit, may influence circulating lipid levels. The rates of hydrolysis increase with increasing amounts of SGS and with increasing substrate concentration, with maximum rates corresponding to substrate concentrations of 7–8 nmol (Baskova et al., 1984). The concentration-dependent kinetics are consistent with standard enzyme-substrate interactions and suggest that SGS lipid-modifying capacity scales with the volume of secretion delivered during a feeding session.

Evidence: SGS Lipid Enzyme Studies

The Role of Thrombin in Atherogenesis

When the endothelium is injured, its protective barrier function breaks down. Platelets adhere to the exposed subendothelial surface, and circulating monocytes, plasma lipids, and proteins gain access to the arterial wall. The injured endothelial cells, recruited monocytes, and activated platelets all release mitogenic factors that drive smooth muscle cell (SMC) migration and proliferation. The resulting endothelial dysfunction triggers an inflammatory response, drawing macrophages and lymphocytes to the injury site. These inflammatory cells secrete hydrolytic enzymes, cytokines, chemokines, and growth factors that promote local tissue necrosis. Combined with receptor-mediated lipid uptake and increased connective tissue production, these processes ultimately give rise to the atherosclerotic plaque (Badimon et al., 1999).

Thrombin is a particularly important driver of SMC proliferation because it acts as a potent mitogen through protease-activated receptors (PARs) on SMCs. Remarkably, even immobilized thrombin that lacks proteolytic activity can stimulate proliferation of bovine aortic SMCs. Thrombin activates early gene c-fos expression and promotes SMC proliferation via an isoprenylation-dependent signaling pathway (Martinez-Gonzales & Badimon, 1996). This mechanism is directly relevant to the anti-atherosclerotic potential of SGS.

Experimental Evidence: SGS Inhibits Intimal Cell Proliferation

Investigation of the effect of SGS on the proliferative activity of cultured human intimal cells from atherosclerotic lesions demonstrated significant antiproliferative activity (Baskova et al., 1989). SGS at a concentration of 5.2 mg/mL reduced ³H-thymidine incorporation by 43–49% after 24 hours in cells from both atherosclerotic lesions and normal aortic segments:

Table 5. Effect of SGS on ³H-Thymidine Incorporation into Cultured Human Aortic Intimal Cells

*p < 0.05 vs. control. SGS concentration: 5.2 mg/mL; incubation: 24 hours (Baskova et al., 1989).

Dose-Response Relationship

The antiproliferative effect was dose-dependent, as demonstrated by serial dilution experiments using donor N1 normal intima cells:

Mechanistic Independence of Antiproliferative and Lipid-Modifying Effects

Incubation with SGS for 2 hours at 37°C did not affect total cholesterol levels in cultured cells from either normal or atherosclerotic aortic segments (Baskova, 1986). This indicates that the antiproliferative and lipid-modifying effects of SGS operate through distinct, independent mechanisms: the former likely through thrombin inhibition (hirudin blocking PAR-mediated mitogenic signaling) and the latter through enzymatic lipid hydrolysis in the extracellular compartment. This mechanistic independence is important because it means the two effects are additive rather than redundant — SGS simultaneously addresses two distinct pathological processes in atherogenesis through independent molecular pathways.

Evidence: SMC Proliferation Studies

The antiatherosclerotic effect of SGS was demonstrated in a controlled animal study. Rats maintained on a special atherogenic diet for 8 months (Bazazyan, 1982) developed lipid intimal swellings characteristic of atherosclerosis in the abdominal and thoracic segments of the aorta. Animals received 7 intravenous injections of SGS in a volume of 0.2 mL; control animals received physiological saline (Baskova et al., 1989).

Aortic Lesion Area Results

Evidence: Animal Model Studies

The endothelium plays a central role in atherosclerosis initiation and progression. Under normal conditions, the endothelium maintains an anticoagulant, anti-inflammatory, and vasodilatory state through continuous production of nitric oxide (NO), prostacyclin (PGI2), and thrombomodulin-mediated protein C activation. Endothelial dysfunction — characterized by reduced NO bioavailability, increased oxidative stress, upregulation of adhesion molecules (VCAM-1, ICAM-1, E-selectin, P-selectin), and increased permeability to lipoproteins — is the earliest detectable event in atherogenesis.

The Inflammatory Hypothesis of Atherosclerosis

The CANTOS trial (Ridker et al., 2017) confirmed the inflammatory hypothesis of atherosclerosis by demonstrating that canakinumab (a monoclonal antibody against IL-1β) reduced cardiovascular events by 15% independently of lipid lowering. This established inflammation as a causal driver of atherosclerotic events, not merely an epiphenomenon. The COLCOT trial (Tardif et al., 2019) and LoDoCo2 trial (Nidorf et al., 2020) subsequently showed that colchicine — a generic anti-inflammatory agent — reduced cardiovascular events by 23–31% in post-MI and chronic coronary disease patients on optimal medical therapy.

SGS contains multiple anti-inflammatory components targeting pathways implicated in atherogenesis:

The following table maps all known SGS components with relevance to atherosclerotic pathways, including their molecular targets, quantitative activity data, mechanisms of action, and primary literature references:

Atherosclerotic Pathway Coverage Map

The preclinical findings described above predate the revolution in cardiovascular pharmacology that has occurred since the 1990s. To assess the clinical relevance of SGS-mediated anti-atherosclerotic mechanisms, they must be placed within the context of current standard-of-care therapies.

Statin Therapy: The Standard of Care

The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) are the cornerstone of modern lipid-lowering therapy. Major clinical trials have demonstrated that statin therapy reduces cardiovascular events by 25–35% and total mortality by 12–30% depending on baseline risk. Statins reduce LDL cholesterol by 30–50% through inhibition of hepatic cholesterol synthesis, upregulation of hepatic LDL receptors, and — importantly — through pleiotropic effects that include improved endothelial function, reduced vascular inflammation, and decreased SMC proliferation.

Landmark Statin Trials

PCSK9 Inhibitors: Next-Generation Lipid Lowering

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors (evolocumab, alirocumab) represent a newer class of lipid-lowering agents that reduce LDL cholesterol by 50–60% when added to statin therapy. By preventing PCSK9-mediated degradation of hepatic LDL receptors, these monoclonal antibodies dramatically increase LDL clearance. The FOURIER trial (Sabatine et al., 2017; N=27,564) demonstrated 15% reduction in the primary composite endpoint and 20% reduction in cardiovascular death, MI, and stroke. The ODYSSEY OUTCOMES trial (Schwartz et al., 2018; N=18,924) confirmed these findings in post-ACS patients, with a mortality signal in the highest-risk quartile (LDL ≥ 100 mg/dL: HR 0.71, p=0.01).

SGS has no known interaction with the PCSK9 pathway. Its mechanism of action is fundamentally different: local enzymatic lipid hydrolysis rather than systemic receptor-mediated clearance. The PCSK9 inhibitor class demonstrates the continued importance of LDL lowering even beyond statin therapy &mdash; supporting the "lower is better" hypothesis for LDL cholesterol and cardiovascular risk.

Anti-Inflammatory Approaches: The Convergence Point

The most relevant modern parallel to SGS's anti-atherosclerotic properties may be the anti-inflammatory approach to cardiovascular disease. Three landmark trials have validated this paradigm:

Antiplatelet and Antithrombotic Therapy

The COMPASS trial (Eikelboom et al., 2017; N=27,395) demonstrated that low-dose rivaroxaban (a factor Xa inhibitor) combined with aspirin reduced the composite of cardiovascular death, stroke, and MI by 24% (HR 0.76, p < 0.001) in patients with stable atherosclerotic disease. This finding is particularly relevant because SGS contains both factor Xa inhibitors (antistasin with Ki ~0.5 nM; lefaxin) and platelet adhesion inhibitors (calin with IC50 ~0.3 nM; saratin) — addressing both sides of the coagulation-platelet axis simultaneously. The COMPASS trial essentially validated the multi-target anticoagulant-antiplatelet approach that SGS naturally embodies.

Evidence: Modern Cardiovascular Landmark Trials

Despite the limitations of the preclinical evidence, SGS presents a compelling model for multi-target intervention in atherosclerosis. The disease involves at least four interacting pathological processes, each addressed by specific SGS components:

The pharmaceutical formulation Piyavit represents an attempt to deliver SGS components systemically. Piyavit is produced from lyophilized leech SGSry gland secretion and administered orally. SGS's high lipid content suggests liposomal structures that may protect bioactive proteins from proteolytic degradation in the gastrointestinal tract and facilitate absorption via pinocytosis.

An honest assessment of the evidence for SGS anti-atherosclerotic activity is essential for clinical decision-making. The following table categorizes all available evidence by type and provides an evidence grade assessment:

SGS has demonstrable lipase (8.2 ± 0.3 nmol FFA/mg protein/hr), cholesterol esterase (3.1 ± 0.3 nmol FFA/mg protein/hr), and antiproliferative activities (43–49% reduction in SMC DNA synthesis) that collectively produce a significant anti-atherosclerotic effect in animal models (85–89% reduction in aortic lesion area). These preclinical findings are mechanistically sound:

• 1. Enzymatic lipid hydrolysis reduces local substrate availability for lipid accumulation in the arterial wall.
• 2. Hirudin-mediated thrombin inhibition (Kd = 20 fM) blocks PAR-dependent SMC proliferation through an isoprenylated-derivative-dependent pathway, operating independently of and additively with lipid-modifying activities.
• 3. Multi-component anti-inflammatory repertoire (eglins, bdellins, LDTI, complement inhibitors, kininases) addresses the inflammatory component of atherogenesis through specific inhibition of neutrophil proteases, mast cell tryptase, complement activation, and kinin-mediated vascular permeability.
• 4. Endothelial protection through prostacyclin analogs and vasodilatory components helps maintain the antithrombotic balance at sites of vascular injury.

However, the evidence remains preclinical and observational. No randomized clinical trial has tested hirudotherapy for atherosclerosis as a primary endpoint. In the modern landscape of cardiovascular pharmacology — where statins, PCSK9 inhibitors, DOACs, and targeted anti-inflammatory agents represent the standard of care — SGS is best understood not as a replacement for these proven therapies but as a historically significant precursor to the multi-target paradigm that now dominates cardiovascular drug development.

The fact that a single biological secretion addresses lipid metabolism, coagulation, platelet function, smooth muscle cell proliferation, and inflammation simultaneously is a testament to the evolutionary sophistication of the leech's pharmacological toolkit — and a reminder that the natural world remains a productive source of therapeutic concepts. For the anticoagulant and antiplatelet mechanisms that contribute to the anti-atherosclerotic effect, see the Hemostasis & Coagulation page. For clinical applications in cardiovascular disease, see Cardiovascular Evidence.